Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Shu-Kui QinFeng BiShanzhi GuYuxian BaiZhendong ChenZishu WangJieer YingYinying LuZhiqiang MengHongming PanPing YangHelong ZhangXi ChenAibing XuChengxu CuiBo ZhuJian WuXiaoli XinJufeng WangJinlu ShanJunhui ChenZhendong ZhengLi XuXiaoyu WenZhenyu YouZhenggang RenXiufeng LiuMeng QiuLiqing WuFeng ChenPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Donafenib showed superiority over sorafenib in improving OS and has favorable safety and tolerability in Chinese patients with advanced HCC, showing promise as a potential first-line monotherapy for these patients.
Keyphrases
- open label
- phase ii
- phase iii
- clinical trial
- phase ii study
- end stage renal disease
- study protocol
- ejection fraction
- newly diagnosed
- chronic kidney disease
- small cell lung cancer
- peritoneal dialysis
- placebo controlled
- prognostic factors
- randomized controlled trial
- double blind
- big data
- combination therapy
- human health
- liver metastases
- radiation therapy
- risk assessment
- climate change
- patient reported